Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
暂无分享,去创建一个
A. Bardelli | M. Buscarino | F. Di Nicolantonio | S. Hobor | S. Misale | E. Valtorta | G. Siravegna | K. Bencardino | A. Sartore-Bianchi | S. Siena | S. Lamba | M. Russo | Federica Di Nicolantonio | Sabrina Arena | Mariangela Russo | Alberto Bardelli | Andrea Sartore-Bianchi | Salvatore Siena | Sandra Misale | Simona Lamba | Giulia Siravegna | Alice Lallo | Sebastijan Hobor | Michela Buscarino | Luca Lazzari | Katia Bencardino | Alessio Amatu | Calogero Lauricella | Emanuele Valtorta | C. Lauricella | A. Amatu | S. Arena | L. Lazzari | A. Lallo
[1] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[2] N. Kemeny. Treatment of metastatic colon cancer: "the times they are A-changing". , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[4] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[5] T. Gilmer,et al. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.
[6] Kate Owen,et al. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.
[7] P. Jänne,et al. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.
[8] A. Grothey,et al. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.
[9] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[10] Levi A Garraway,et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. , 2012, Cancer discovery.
[11] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[12] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[13] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[14] A. Ashworth,et al. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.
[15] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[16] M. Ladanyi,et al. HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation , 2012 .
[17] S. Goodman,et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. , 2008, Gastroenterology.
[18] S. Chadda,et al. A systematic review of treatment guidelines for metastatic colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[19] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[20] Francesco Prati,et al. From bench to bedside: a novel technique of acquiring OCT images. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[21] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[22] Barry S Taylor,et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. , 2010, Cancer research.
[23] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[24] L. Trümper. From bench to bedside , 2005, Medizinische Klinik.
[25] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.
[26] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[27] T. Sparks,et al. The times they are a-changing? , 1999, Bird Conservation International.
[28] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[29] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[30] A. Bardelli,et al. Targeted therapies: how personal should we go? , 2012, Nature Reviews Clinical Oncology.
[31] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[32] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[33] Suzie K. Hight,et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. , 2010, Gastroenterology.
[34] C. G. Baker. The Ludwig Institute for cancer research , 1982 .
[35] Andrea Bertotti,et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.
[36] W. Samowitz,et al. Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. , 2011, Archives of pathology & laboratory medicine.
[37] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[38] J C Winck,et al. Times they are a-changing. , 2010, Revista portuguesa de pneumologia.
[39] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[40] R. Murthy,et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Bertagnolli,et al. Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.
[42] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[43] I. Nagtegaal,et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy , 2013, International journal of cancer.
[44] Delong Liu,et al. MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.
[45] William Pao,et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.
[46] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[47] A. Batistatou,et al. Molecular basis of colorectal cancer. , 2010, The New England journal of medicine.
[48] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[49] R. Whitehead,et al. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. , 1985, Journal of the National Cancer Institute.
[50] F. Ciardiello,et al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors , 2011, British Journal of Cancer.
[51] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.